Cassava Sciences, Inc. (SAVA)
收市後：
| 前收市價 | 22.06 |
| 開市 | 22.15 |
| 買盤 | 22.03 x 100 |
| 賣出價 | 22.09 x 100 |
| 今日波幅 | 21.99 - 22.36 |
| 52 週波幅 | 12.32 - 32.10 |
| 成交量 | |
| 平均成交量 | 785,721 |
| 市值 | 953.57M |
| Beta 值 (5 年，每月) | -0.40 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.32 |
| 業績公佈日 | 2024年5月06日 - 2024年5月17日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2012年12月13日 |
| 1 年預測目標價 | 無 |
InvestorPlaceExit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas
Motley FoolIs There Any Hope for Cassava Sciences Stock?
Battered by controversy, this company will need to show real results to prosper.
InvestorPlace3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies’ performance relies heavily on drug approvals. A major drug approval has the potential to multiply stock price several times, while a failure to reach approval may cause an immediate, sharp decline. For the following reasons, it is important to choose biotech investments carefully. Below are th
